Loading
IZABRIGHT-Breast01 is the global first-line trial of the EGFR×HER3 bispecific ADC in triple-negative breast cancer.
IZABRIGHT-Breast01, trial NCT06926868 sponsored by Bristol Myers Squibb, is the global first-line trial of the EGFR by HER3 bispecific antibody-drug conjugate izalontamab brengitecan in metastatic triple-negative breast cancer patients ineligible for PD-1 or PD-L1 inhibitors, comparing it with chemotherapy. It plans to enrol 570 patients, directly competes for the populations studied in ASCENT-03 and TROPION-Breast02, and is ongoing with no results. OnCo links it to triple-negative breast cancer, izalontamab brengitecan and the TNBC roadmap. Whether a bispecific ADC that succeeded in a Chinese phase 3 can match or beat the approved TROP2 ADCs in a global first-line population is the question it exists to answer.
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, Bispecific ADC, Izalontamab brengitecan, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares Bispecific ADC, Izalontamab brengitecan, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, Antibody-drug conjugate (ADC).
Shares Trials that include, and report, brain metastases in triple-negative breast cancer, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Metastatic triple-negative breast cancer.
Shares Bispecific ADC, Izalontamab brengitecan, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, Antibody-drug conjugate (ADC).